| Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England Journal of Medicine 379 (22), 2108-2121, 2018 | 3764 | 2018 |
| Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results … P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ... The Lancet Oncology 21 (1), 44-59, 2020 | 1039 | 2020 |
| Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple … EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung, R Hegg, A Koehler, ... The Lancet 396 (10257), 1090-1100, 2020 | 791 | 2020 |
| Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ... JAMA oncology 5 (1), 74-82, 2019 | 690 | 2019 |
| First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis LA Emens, S Adams, CH Barrios, V Diéras, H Iwata, S Loi, HS Rugo, ... Annals of Oncology 32 (8), 983-993, 2021 | 281 | 2021 |
| Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial S Adams, JR Diamond, E Hamilton, PR Pohlmann, SM Tolaney, ... JAMA oncology 5 (3), 334-342, 2019 | 268 | 2019 |
| TLR engagement prevents transplantation tolerance L Chen, T Wang, P Zhou, L Ma, D Yin, J Shen, L Molinero, T Nozaki, ... American Journal of Transplantation 6 (10), 2282-2291, 2006 | 251 | 2006 |
| Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39) KN Moore, M Bookman, J Sehouli, A Miller, C Anderson, G Scambia, ... Journal of Clinical Oncology 39 (17), 1842, 2021 | 219 | 2021 |
| Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study LA Emens, L Molinero, S Loi, HS Rugo, A Schneeweiss, V Diéras, H Iwata, ... JNCI: Journal of the National Cancer Institute 113 (8), 1005-1016, 2021 | 209 | 2021 |
| Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) LA Emens, FS Braiteh, P Cassier, JP Delord, JP Eder, M Fasso, Y Xiao, ... Cancer Research 75 (15_Supplement), 2859-2859, 2015 | 188 | 2015 |
| Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). S Adams, JR Diamond, EP Hamilton, PR Pohlmann, SM Tolaney, ... Journal of clinical oncology 34 (15_suppl), 1009-1009, 2016 | 167 | 2016 |
| Role of natural killer cell subsets in cardiac allograft rejection ME McNerney, KM Lee, P Zhou, L Molinero, M Mashayekhi, D Guzior, ... American journal of transplantation 6 (3), 505-513, 2006 | 155 | 2006 |
| Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity MB Fuertes, MV Girart, LL Molinero, CI Domaica, LE Rossi, MM Barrio, ... The Journal of Immunology 180 (7), 4606-4614, 2008 | 148 | 2008 |
| β-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells S Keerthivasan, K Aghajani, M Dose, L Molinero, MW Khan, ... Science translational medicine 6 (225), 225ra28-225ra28, 2014 | 145 | 2014 |
| NF-κB regulates expression of the MHC class I-related chain A gene in activated T lymphocytes LL Molinero, MB Fuertes, MV Girart, L Fainboim, GA Rabinovich, ... The Journal of Immunology 173 (9), 5583-5590, 2004 | 145 | 2004 |
| CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells LL Molinero, J Yang, T Gajewski, C Abraham, MA Farrar, ML Alegre The Journal of Immunology 182 (11), 6736-6743, 2009 | 140 | 2009 |
| Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses P Schmid, C Cruz, FS Braiteh, JP Eder, S Tolaney, I Kuter, R Nanda, ... Cancer Research 77 (13_Supplement), 2986-2986, 2017 | 138 | 2017 |
| Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma RV Lukas, J Rodon, K Becker, ET Wong, K Shih, M Touat, M Fassò, ... Journal of neuro-oncology 140, 317-328, 2018 | 135 | 2018 |
| Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 HS Rugo, S Loi, S Adams, P Schmid, A Schneeweiss, CH Barrios, H Iwata, ... Annals of Oncology 30, v858-v859, 2019 | 128 | 2019 |
| Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial AD Colevas, R Bahleda, F Braiteh, A Balmanoukian, I Brana, NG Chau, ... Annals of Oncology 29 (11), 2247-2253, 2018 | 120 | 2018 |
